

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addines: COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/644,579	08/20/2003	Connie Sanchez	05432/100M919-US1	5200
7278 7590 08/14/2009 DARBY & DARBY P.C. P.O. BOX 770			EXAMINER	
			CHONG, YONG SOO	
Church Street Station New York, NY 10008-0770			ART UNIT	PAPER NUMBER
			1617	
			MAIL DATE	DELIVERY MODE
			08/14/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Interview Summary

 Application No.
 Applicant(s)

 10/644,579
 SANCHEZ ET AL.

 Examiner
 Art Unit

 Yong S. Chong
 1617

All participants (applicant, applicant's representative, PTO personnel):
(1) <u>Yong S. Chong</u> . (3) <u>Mr. Jay Leffler</u> .
(2) <u>Ms. Dianna Goldenson</u> . (4)
Date of Interview: <u>13 August 2009</u> .
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2)□ applicant's representative]
Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No. If Yes, brief description:
Claim(s) discussed: 20-40.
Identification of prior art discussed: <u>yes</u> .
Agreement with respect to the claims f) \square was reached. g) \square was not reached. h) \square N/A.
Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments. <u>Applicant arques unexpected results as reported in the Zimbroff study of record. It was reported that patients who did not respond to initial treatment with citalopram surprisingly responded to escitalopram, the opticality pure form. As mentioned before, this data and line of reasoning is not persuasive because there is no showing of unexpected results since the cited prior at teaches that the antidepressant activity resides in escitalopram. (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS INTERVIEW DATE, OR THE MALING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.</u>
Yong S. Chong/ Primary Examiner, Art Unit 1617